Skip to content
10-K

Annual Report

Indivior Pharmaceuticals, Inc. INDV

0001628280-26-012237

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jan 31, 2026 125.07M sh
Shares Diluted FY 2025 · Dec 31, 2025 128M sh
Shares Diluted FY 2025 · Dec 31, 2024 133M sh
Shares Diluted FY 2025 · Dec 31, 2023 137M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $11M
Stock Repurchased FY 2025 · Dec 31, 2024 $173M
Stock Repurchased FY 2025 · Dec 31, 2023 $33M
Capex FY 2025 · Dec 31, 2025 $66M
Capex FY 2025 · Dec 31, 2024 $29M
Capex FY 2025 · Dec 31, 2023 $8M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$27M
Operating Cash Flow FY 2025 · Dec 31, 2024 $36M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$300M
Long Term Debt FY 2025 · Dec 31, 2025 $290M
Long Term Debt FY 2025 · Dec 31, 2024 $315M
Short Term Debt FY 2025 · Dec 31, 2025 $29M
Short Term Debt FY 2025 · Dec 31, 2024 $18M
Short Term Investments FY 2025 · Dec 31, 2025 $0
Short Term Investments FY 2025 · Dec 31, 2024 $1M
Cash And Equivalents FY 2025 · Dec 31, 2025 $195M
Cash And Equivalents FY 2025 · Dec 31, 2024 $319M
Stockholders Equity FY 2025 · Dec 31, 2025 −$98M
Stockholders Equity restated FY 2025 · Dec 31, 2024 −$337M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$184M
Stockholders Equity restated FY 2025 · Dec 31, 2022 −$15M
Current Liabilities FY 2025 · Dec 31, 2025 $914M
Current Liabilities restated FY 2025 · Dec 31, 2024 $924M
Current Liabilities restated FY 2025 · Dec 31, 2023 $1.28B
Total Liabilities FY 2025 · Dec 31, 2025 $1.3B
Total Liabilities restated FY 2025 · Dec 31, 2024 $1.65B
Total Liabilities restated FY 2025 · Dec 31, 2023 $1.94B
Current Assets FY 2025 · Dec 31, 2025 $652M
Current Assets restated FY 2025 · Dec 31, 2024 $827M
Current Assets restated FY 2025 · Dec 31, 2023 $1.26B
Total Assets FY 2025 · Dec 31, 2025 $1.2B
Total Assets restated FY 2025 · Dec 31, 2024 $1.32B
Total Assets restated FY 2025 · Dec 31, 2023 $1.76B
Eps Diluted FY 2025 · Dec 31, 2025 $1.64
Eps Diluted restated FY 2025 · Dec 31, 2024 $0.05
Eps Diluted restated FY 2025 · Dec 31, 2023 −$0.92
Eps Basic FY 2025 · Dec 31, 2025 $1.68
Eps Basic restated FY 2025 · Dec 31, 2024 $0.05
Eps Basic restated FY 2025 · Dec 31, 2023 −$0.92
Sga Expense FY 2025 · Dec 31, 2025 $634M
Sga Expense FY 2025 · Dec 31, 2024 $175M
Sga Expense restated FY 2025 · Dec 31, 2024 $612M
Sga Expense FY 2025 · Sep 30, 2024 $142M
Sga Expense FY 2025 · Jun 30, 2024 $152M
Sga Expense FY 2025 · Mar 31, 2024 $143M
Sga Expense restated FY 2025 · Dec 31, 2023 $565M
Net Income FY 2025 · Dec 31, 2025 $210M
Net Income FY 2025 · Dec 31, 2024 $21M
Net Income restated FY 2025 · Dec 31, 2024 $7M
Net Income FY 2025 · Sep 30, 2024 $22M
Net Income FY 2025 · Jun 30, 2024 −$97M
Net Income FY 2025 · Mar 31, 2024 $61M
Net Income restated FY 2025 · Dec 31, 2023 −$126M
Operating Income FY 2025 · Dec 31, 2025 $262M
Operating Income FY 2025 · Dec 31, 2024 $46M
Operating Income restated FY 2025 · Dec 31, 2024 $38M
Operating Income FY 2025 · Sep 30, 2024 $35M
Operating Income FY 2025 · Jun 30, 2024 −$118M
Operating Income FY 2025 · Mar 31, 2024 $75M
Operating Income restated FY 2025 · Dec 31, 2023 −$152M
Gross Profit FY 2025 · Dec 31, 2025 $994M
Gross Profit FY 2025 · Dec 31, 2024 $957M
Gross Profit FY 2025 · Dec 31, 2023 $919M
Cost Of Revenue FY 2025 · Dec 31, 2025 $246M
Cost Of Revenue FY 2025 · Dec 31, 2024 $231M
Cost Of Revenue FY 2025 · Dec 31, 2023 $174M
Revenue FY 2025 · Dec 31, 2025 $1.24B
Revenue FY 2025 · Dec 31, 2024 $1.19B
Revenue FY 2025 · Dec 31, 2023 $1.09B